1. Home
  2. FRD vs SPRO Comparison

FRD vs SPRO Comparison

Compare FRD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$34.66

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.83

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
SPRO
Founded
1965
2013
Country
United States
United States
Employees
N/A
25
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
156.3M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
FRD
SPRO
Price
$34.66
$2.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.5K
861.4K
Earning Date
06-11-2026
05-13-2026
Dividend Yield
0.79%
N/A
EPS Growth
N/A
111.81
EPS
1.46
N/A
Revenue
$121,157,278.00
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
$18.07
N/A
Revenue Growth
55.82
39.24
52 Week Low
$14.52
$1.80
52 Week High
$26.50
$3.09

Technical Indicators

Market Signals
Indicator
FRD
SPRO
Relative Strength Index (RSI) 92.37 54.76
Support Level $17.90 $2.18
Resistance Level N/A $3.07
Average True Range (ATR) 1.36 0.18
MACD 0.75 -0.02
Stochastic Oscillator 89.50 57.50

Price Performance

Historical Comparison
FRD
SPRO

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: